Sitagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with short bowel syndrome and colon in continuity: an open-label pilot study.

Rahim Mohammad NaimiMark Krogh HvistendahlLise Margrete ThomassenHanna JohnsenCharlotte Bayer ChristiansenJens Juul HolstBolette HartmannPalle Bekker Jeppesen

Published in: BMJ open gastroenterology (2021)

Following this negative, small pilot study, larger, placebo-controlled, studies are needed to establish the therapeutic potential of DPP-4 inhibition in patients with SBS.

Keyphrases

placebo controlled
double blind
study protocol
case report
randomized controlled trial
phase ii
clinical trial
squamous cell carcinoma
open label
locally advanced